Detalles de la búsqueda
1.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982686
2.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776843
3.
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
JAMA Surg
; 158(8): 807-815, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37285140
4.
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Eur Urol
; 84(6): 571-578, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37758574
5.
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Oncol Res Treat
; 45(5): 272-280, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045416
6.
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.
Cancers (Basel)
; 12(11)2020 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33121007
7.
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
Clin Colorectal Cancer
; 19(4): 236-247.e6, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32737003
8.
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Oncotarget
; 8(28): 45898-45917, 2017 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28507280
9.
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
J Thorac Oncol
; 12(1): 54-64, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575422
10.
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Urol Oncol
; 34(4): 167.e21-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26699830
11.
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Eur J Cancer
; 49(15): 3076-82, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23876834
12.
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
J Cancer Res Clin Oncol
; 138(8): 1385-94, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22488173
13.
Therapeutic targeting of apoptotic pathways in cancer.
Curr Drug Targets
; 7(10): 1361-9, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17073598
Resultados
1 -
13
de 13
1
Próxima >
>>